The incidence of serious adverse reactions associated with donation of haematopoietic stem cells by unrelated donors was recently reviewed and reported to be low by Pulsipher et al. 1 Macroscopic haematuria was however reported on three occasions following PBSC donation despite strict donor selection criteria and a thorough medical workup to establish the medical suitability of a given donor. Recently we have encountered three cases of haematuria in stem cell donors, two at the Anthony Nolan unrelated donor registry and one case from the Ulster Hospital renal unit, highlighting that serious underlying medical conditions may go unnoticed despite rigorous assessment.
A 28-year-old Caucasian male listed on the Anthony Nolan donor register was selected as an HLA-matched unrelated donor for a patient in need of a haematopoietic stem cell transplant. He had declared no serious medical conditions at earlier stages of donor procurement, and was approved to continue to medical workup. At workup, he reported an episode of self-limiting visible haematuria 1 year previously. A renal ultrasound at the time was normal, and he was diagnosed with an assumed episode of haemorrhagic cystitis, probably due to a urinary tract infection. He had no further episodes of haematuria following this. He was physically well with a normal examination on the day of workup.
Before donation his routine laboratory tests were within local reference ranges (including full blood count, urea and electrolytes, calcium, phosphate, liver function tests, coagulation, haemoglobinopathy screen, blood grouping and Ab screening, and infectious disease markers). Of note, the creatinine was 95 μmol/L. Electrocardiogram and chest X-ray was normal. Urinalysis was not performed at this time as per local registry screening policy. He was declared medically fit to donate by G-CSF mobilised PBSC harvest. He commenced a 4-day course of lenograstim (recombinant glycosylated G-CSF, Granocyte) at 10 μg/kg daily.
He developed lower back discomfort after the first dose of G-CSF, a common adverse event. However, shortly after administration of the third dose of G-CSF, he developed visible haematuria with no other associated symptoms. He was admitted to the collection centre, where the decision was made to omit the planned fourth dose of G-CSF, but to proceed with PBSC harvest the following day. He had an uneventful collection, yielding a stem cell dose of 2.46 × 10 6 /L CD34+ cells (target 4.0 × 10 9 ). On the day of collection however, his creatinine increased to 148 μmol/L and urinalysis performed showed visible haematuria and nephrotic range proteinuria (4.1 g per day). His renal immunological screen was negative for autoantibodies: antinuclear antibodies (ANA) and anti-neutrophil cytoplasm antibodies (ANCA). One day after donation his creatinine fell to 130 μmol/L and his haematuria became microscopic and non-visible. He was reviewed by a nephrologist and, in view of his reassuring clinical and laboratory indices, was discharged to local follow-up. He was seen 1 week later by local renal services and a presumptive diagnosis of IgA nephropathy was made and he was commenced on an ACE inhibitor. This was later confirmed by immunofluorescence and EM performed on a renal biopsy. Features of IgA nephropathy with mesangial proliferative glomerulonephritis and secondary segmental glomerulosclerosis were seen. His biochemical indices resolved soon after donation, although proteinuria and microscopic haematuria persisted 5 months later.
We encountered a similar case more recently, when another 28-year-old Caucasian male donor, with an unremarkable medical history, developed darkening of the urine after three doses of G-CSF with associated symptoms of bone and muscle aches. This developed into visible haematuria over the following 2 days. A fourth dose of G-CSF was nevertheless administered as the symptoms were not reported at the time. The donor had an uneventful collection and yielded 5.5 × 10 6 /L CD34+ cells (target 4.0 × 10 9 ). His creatinine was 77 μmol/L on the day of collection and his urine dipstick showed heavy haematuria but no proteinuria. Five days post donation he underwent a renal ultrasound and a contrast-enhanced computed tomography scan of his kidneys, ureters and bladder, which was unremarkable. Quantitative urinalysis at this stage revealed nephrotic range proteinuria of~5 g/L. An autoantibody screen was negative for ANA and ANCA. His renal function and blood pressure remained normal throughout and his visible haematuria eventually resolved. Two weeks following donation he was reviewed by a nephrologist and his proteinuria had improved to~0.5 g/day. A presumptive diagnosis of IgA nephropathy was suggested but it was felt that a renal biopsy was not indicated given the improvement of his clinical and laboratory indices including his proteinuria.
The third case encountered was in a 54-year-old Caucasian female with no significant past medical history that, following G-CSF mobilisation to enable donation for her sister, also developed visible haematuria. Her pre-donation creatinine was 84 μmol/L. Urinalysis at the time of donation showed heavy haematuria and proteinuria. Unfortunately the proteinuria was not quantified. Her creatinine peaked at 118 μmol/L but subsequently settled to 90 μmol/L. She was referred to nephrology services 3 weeks later, after a 24 h urinary protein excretion of 0.8 g was measured at her local GP. An autoantibody screen was negative for ANA and ANCA and serum complement levels were normal. Bedside renal ultrasound showed two structurally normal kidneys. Her blood pressure was normal at 108/67 mm Hg and her renal function had recovered to baseline with a creatinine of 88 μmol/L. Her proteinuria improved further to~0.3 g/day. A presumptive diagnosis of IgA nephropathy was made and as her renal function remained well preserved with minimal proteinuria a renal biopsy was felt not to be warranted.
In summary, these cases illustrate one proven and two probable cases of pre-existing IgA nephropathy exacerbated by administration of G-CSF. In most published series, [2] [3] [4] 30-60% of patients with IgA nephropathy (IgAN) are diagnosed following kidney biopsy after asymptomatic urine testing. IgAN can present with a wide range of clinical features but is usually of a male preponderance, with apparent peak incidences in the second and third decades of life and can have a variable time course of disease following diagnosis. 2 The incidence of IgAN worldwide is presumed to be at least 2.5/100 000/year in adults 3 but there is large variability depending on geographical location (0.05/100-000/year in Venezuela and 4.5/100 000/year in Japan).
3 Similar variability is seen in the prevalence of IgAN and a recent study showed figures of 4% in Brazil to as high as 51% in Japan. 5 From studies of renal biopsies in the UK between 1978-2005, prevalence figures for IgAN range from 14 to 39%. 5 Thus the incidence and prevalence of the disease is probably underestimated because the criteria for a kidney biopsy (which is required for diagnosis) are variable globally. 2, 3, 5 The use of G-CSF has previously been linked to incidences of glomerulonephritis. Although usually self-limiting, some have been associated with acute kidney injury requiring dialysis. 2, 6 In the literature, IgAN was identified on biopsy in a 7-year-old boy from Japan, 4 and a 44-year-old woman developed macroscopic haematuria after G-CSF administration for PBSC donation with focal segmental proliferative glomerulonephritis on kidney biopsy. 7 G-CSF use in severe congenital neutropenia has also been associated with other glomerulonephritides. Miller et al. 8 identified a donor with a history of benign microscopic haematuria that progressed to macroscopic haematuria. This resolved spontaneously 6 weeks after donation and the donor returned to a baseline level of benign macroscopic haematuria. The Serious Events and Adverse Reactions database held by the World Marrow Donor Association (WMDA) reports one additional episode of unexplained haematuria in G-CSF mobilised donors. 9 The cases identified very likely represent an underestimated population of at-risk patients, with undiagnosed IgAN. Nephrologists now recommend that patients with asymptomatic haematuria, in the absence of sustained proteinuria do not require a renal biopsy, and so most will remain undiagnosed. With current evidence however, we do not know whether exacerbation of this condition following administration of G-CSF has an impact on the natural history of the disease or the likelihood of the donor developing progressive chronic kidney disease in the future. We would therefore urge all donor registries to report any further cases to the WMDA. We would also recommend the introduction of urinalysis as part of the medical workup in all haematopoietic stem cell donors with appropriate follow-up management arranged as shown in Figure 1 .
